High sensitivity detection of activated factor IX: Application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes

Thrombosis and Haemostasis

Volumn 79, Issue 4, 1998, Pages 778-783

  Kusch, Manuela ^a   Seitz, Rainer ^a   König, Herbert ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9A; FLUORESCENT DYE; PROTHROMBIN;

ARTICLE; AUTOANALYSIS; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME ASSAY; PRIORITY JOURNAL; RELIABILITY; SCREENING TEST; THROMBOGENICITY;

EID: 0031957358     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615064     Document Type: Article

References (30)

1. Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Haemostasis and Thrombosis, 3rd edition. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds., 1994; 169-83.
2. Bick RL. Principles of clinical practice. In: Disorders of haemostasis and thrombosis. Georg Thieme Verlag, Stuttgart, New York 1985.
3. Scharrer I. The need for highly purified products to treat haemophilia B. Acta haematol 1995; 94 (suppl): 2-7.
4. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston FE. Emergency oral anticoagulant reversal: The relative efficiency of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
5. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-7.
6. Brozovic M. Acquired disorders of coagulation, in: Haemostasis and Thrombosis, 2nd edition. Bloom AL, Duncan PT, eds., 1987: 519-34.
7. Ohga S, Saito M, Matsukazi A, Kai T, Ueda K. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy. Br J Haematol 1993; 84: 343-5.
8. Gruen DR, Winchester PH, Brill PW, Ramirez E. Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A. Pediatric Radiology 1997; 27: 271-2.
9. Chistolini A, Mazzucconi MG, Tirindelli MC, La Verde G, Ferrari A, Mandelli F. Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates. Acta haematologica 1990; 83: 163-5.
10. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-31.
11. Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028-38.
12. Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-37.
13. Giles AR, Nesheim ME, Hoogendorn H, Tracy PB, Mann KG. The coagulant active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-7.
14. Berntorp E. Why prescribe highly purified factor VIII and IX concentrates? Vox Sanguinis 1996; 70: 61-8.
15. Roberts HR, Eberst ME. Current management of haemophilia B. Hematology Oncology Clinics of North America 1993; 7: 1269-80.
16. Hampton KK, Preston FE, Lowe GDO, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-84.
17. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-11.
18. Harrison J, Abildgaard C, Lazerson J, Culbertson R., Anderson G. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model. Thromb Res 1985; 38: 173-88.
19. Smith KJ. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals. Blood 1988; 72: 1269-77.
20. Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EGD, Lowe GDO, Rumley A, Ludlam CA. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76: 23-8.
21. Gray E, Tubbs J, Oates TA, Boisclair M, Kemball-Cook G, Barrowcliffe TW. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-79.
22. Kawabata S, Miura T, Morita T, Kato H, Fujikawa K, Iwanaga S, Takada K, Kimura T, Sakakibara S. Highly sensitive peptide-4-methyl-coumaryl 7-amide substrates for blood clotting proteases and trypsin. Eur J Biochem 1988; 172: 17-25.
23. Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chloromethyl ketones. J Biol Chem 1989; 264: 7536-44.
24. Hashimoto N, Morita T, Iwanaga S. A method for systematic purification from bovine plasma of six vitamin K dependent coagulation factors: Prothrombin, factor X, factor IX, protein S, protein C, and protein Z. J Biochem 1985; 97: 1347-55.
25. Furie BC, Furie B. Coagulant protein of Russel's viper venom. Methods in enzymology. Lorand L (ed.). New York: Academic press 1976; 45: 191.
26. Marsman FR. Parallel line assay: Calculation of potency and 95% confidence limits, version 94-1; in: Manual of laboratory methods for testing the potency of final vaccines used in the WHO expanded programme on immunization. WHO BLG/95.1.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 1979; 76: 4350-4.
29. Schaffner W, Weissmann C. A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal Biochem 1973; 56: 502-14.
30. Kemkes-Matthes B, Matthes KJ. Protein Z deficiency-a new type of bleeding disorder. Annals of Haematology 1993; 66: suppl 1: A 39.